A detailed history of Dimensional Fund Advisors LP transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 456,166 shares of PLRX stock, worth $6.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
456,166
Previous 305,322 49.4%
Holding current value
$6.07 Million
Previous $3.28 Million 55.79%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$10.52 - $14.35 $1.59 Million - $2.16 Million
150,844 Added 49.4%
456,166 $5.11 Million
Q2 2024

Aug 09, 2024

BUY
$10.58 - $15.61 $54,508 - $80,422
5,152 Added 1.72%
305,322 $3.28 Million
Q1 2024

May 10, 2024

BUY
$14.14 - $19.59 $2.07 Million - $2.86 Million
146,098 Added 94.82%
300,170 $4.47 Million
Q4 2023

Feb 07, 2024

BUY
$12.85 - $19.15 $1.25 Million - $1.87 Million
97,420 Added 171.96%
154,072 $2.79 Million
Q3 2023

Nov 09, 2023

SELL
$14.58 - $20.15 $1.08 Million - $1.49 Million
-74,059 Reduced 56.66%
56,652 $982,000
Q2 2023

Aug 09, 2023

SELL
$18.12 - $30.56 $1.48 Million - $2.5 Million
-81,745 Reduced 38.48%
130,711 $2.37 Million
Q1 2023

May 12, 2023

BUY
$18.73 - $36.26 $1.28 Million - $2.48 Million
68,489 Added 47.57%
212,456 $5.65 Million
Q4 2022

Feb 09, 2023

BUY
$17.0 - $25.43 $2.11 Million - $3.16 Million
124,106 Added 624.87%
143,967 $2.78 Million
Q3 2022

Nov 10, 2022

BUY
$7.67 - $24.23 $39,531 - $124,881
5,154 Added 35.04%
19,861 $415,000
Q2 2022

Aug 12, 2022

BUY
$4.11 - $8.75 $5,030 - $10,710
1,224 Added 9.08%
14,707 $118,000
Q1 2022

May 13, 2022

BUY
$7.01 - $14.1 $94,515 - $190,110
13,483 New
13,483 $95,000

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $647M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.